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a  b  s  t  r  a  c  t
Thelazia  callipaeda  (Spirurida,  Thelaziidae)  has been  documented  as  agent  of  ocular  infection  in  domestic
animals  (dogs  and  cats),  wildlife  (e.g.,  foxes, hares,  rabbits),  and  humans.  In the  last  two  decades,  this  par-
asitosis  has  been  increasingly  reported  in  several  European  countries.  Both  adult  and  larval  stages  of  the
eyeworm  are  responsible  for symptoms  ranging  from  mild  (e.g.,  lacrimation,  ocular  discharge,  epiphora)
to severe  (e.g., conjunctivitis,  keratitis,  and  corneal  opacity  or ulcers).  The  present  study  evaluated  the
clinical  efﬁcacy  and  safety  of imidacloprid  10%  and  moxidectin  2.5% spot  on (Advocate®, Bayer  Animal
Health)  in  comparison  to milbemycin  oxime/praziquantel  tablets  (Milbemax®, Novartis-Animal  Health),
as positive  control,  in  the  treatment  of canine  thelaziosis  in naturally  infected  dogs  and,  a third  group
was  used  as  an  untreated  control.  Forty-seven  dogs  (27  females  and  20  males)  harbouring  at  least  one
live adult  worm  of  T.  callipaeda  in one  eye  were  enrolled  from  an  endemic  area  of southern  Italy.  Each
dog  was  then  weighed  and  assigned  in  accordance  with  a random  treatment  allocation  plan  to one  of
the  treatment  groups  (G1:  imidacloprid  10%  and  moxidectin  2.5%  spot  on,  G2:  Untreated  control  and  G3:
milbemycin  oxime/praziquantel  tablets).  On Day  (D)  7, 14,  28  and  35  dogs  were  physically  examined  and
the infection  level  was  assessed  by examination  of both  eyes,  including  conjunctival  pouch  and  third  eye-
lid for  live  adult  T.  callipaeda  count  and  clinical  scores.  Dogs  in G1 were  treated  on  D0 and  D28,  whereas
those  in  G3  on  D0  and  D7.  Efﬁcacy  in  G1  was  100%  at each  day  post  treatment  (p  <  0.01).  For  the  G3 group
efﬁcacy  was  57.39%  on  D7  (p < 0.05),  92.79%  on D14  and  100%  on  D28  and  D35 (p  < 0.01).  The  application
of  the spot  on  formulation  moxidectin  2.5%  and  imidacloprid  10%  was  highly  effective  in the  treatment
of  canine  thelaziosis  caused  by  T. callipaeda.  Advocate® spot  on  can  be recommended  for the  control  of
T. callipaeda  infection,  considering  that  this  formulation  is  currently  licensed  in  Europe  for the  treatment
of  a  wide  range  of  parasites  affecting  dogs.
© 2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Since the ﬁrst diagnosis of eyeworm infection by Thelazia calli-
aeda (Spirurida, Thelaziidae) in dogs from northern Italy (Rossi and
ertaglia, 1989), this parasitosis has been increasingly reported in
everal European countries including Italy, Belgium, France, Greece,
ortugal, Spain, and Switzerland (Diakou et al., 2015; Otranto et al.,
∗ Corresponding author.
E-mail address: domenico.otranto@uniba.it (D. Otranto).
ttp://dx.doi.org/10.1016/j.vetpar.2016.07.035
304-4017/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2015). In Europe, T. callipaeda has been documented as agent of
ocular infection in domestic animals (dogs and cats) and wildlife
(e.g., foxes, hares, rabbits) (Otranto et al., 2009). Recently the num-
ber of cases of thelaziosis in dogs, cats and foxes living in Eastern
European countries has surged (Hodzˇic´ et al., 2014; Tasic´-Otasˇevic´
et al., 2016; Colella et al., 2016). Due to the former distribution in
East Asian countries (e.g., China, Thailand, Japan and many oth-
ers) this nematode was  referred as the “oriental eye-worm” being
recognised also as a causative agent of human infection (Shen et al.,
2006). However, due to the large number of reports in European
countries this common name of T. callipaeda is no longer appropri-
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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D28, D35. Therapeutic efﬁcacy (%) in the treatment of T. callipaedaFig. 1. Eyeworm infection by Thelazia callipaeda in a dog.
te. In Europe, cases of human thelaziosis have been reported in
taly (Otranto and Dutto, 2008), Spain (Fuentes et al., 2012), Croatia
Paradzˇik et al., 2016) and, Serbia (Tasic´-Otasˇevic´ et al., 2016) where
utochthonous infections are well established in animal popula-
ion. The increased number of eyeworm infections in both animals
nd humans is related to the presence of Phortica variegata (Diptera,
rosophilidae, Steganinae) that acts as the intermediate host of T.
allipaeda in Europe (Otranto et al., 2006; Máca and Otranto, 2014)
hile feeding on lachrymal secretions of infected animals.
Both adult and larval stages of the eyeworm are responsible for
ymptoms ranging from mild (e.g., lacrimation, ocular discharge,
piphora) to severe (e.g., conjunctivitis, keratitis and, corneal opac-
ty or ulcers), also related to the load of parasites inhabiting the
rbital cavity (Shen et al., 2006). Nematodes (i.e. adult and larvae)
ay  be removed mechanically by rinsing the conjunctival sac with
aline solutions and adults may  be collected with ﬁne forceps or
wabs (Shen et al., 2006).
Successful treatment of eyeworm infection included topic
nstillation of organophosphates (Rossi and Peruccio, 1989) or
oxidectin 1% (Lia et al., 2004) which were effective against T. cal-
ipaeda. Nonetheless, topical administration is an off label use and
ay  be irritant to the ocular tissues, therefore it is unacceptable in
eterinary practice. Additionally, milbemycin oxime/praziquantel
ablets (Milbemax®, Novartis-Animal Health), at the minimal dose
f 0.5 mg/kg milbemycim oxime, have shown to signiﬁcantly
educe infection rate in naturally infected dogs and cats (Motta
t al., 2012) and it is the only product so far registered for the treat-
ent of canine thelaziosis in Europe. Meanwhile, imidacloprid 10%
nd moxidectin 2.5% spot-on formulation was shown to be effec-
ive for the treatment and prevention of dog thelaziosis (Bianciardi
nd Otranto, 2005; Lechat et al., 2015).
The aim of this study was to evaluate the clinical efﬁcacy and
afety of imidacloprid 10% and moxidectin 2.5% spot-on, in compar-
son to milbemycin oxime/praziquantel tablets as positive control,
n the treatment of canine thelaziosis in naturally infected dogs.
. Materials and methods
This study was conducted as a GCP negative and positive con-
rolled, blinded and randomised ﬁeld study in privately owned dogs
iving in a T. callipaeda endemic area of Basilicata region (south-
rn Italy). Study animals were located in areas endemic for canine
helaziosis where the presence of the vector and of the disease in
ogs was already reported (Otranto et al., 2003a). Forty-seven dogs
27 females and 20 males) aged 7 months to 13 years, of differ-
nt breeds, in good health condition and with at least one live T.
allipaeda adult in one eye were included in the study (Fig. 1), fol-itology 227 (2016) 118–121 119
lowing collection of informed owner consent form. Details of study
population are provided in Table 1.
At inclusion (Day (D) 0), animals were physically examined
and both eyes were inspected, including a thorough examination
underneath the third eyelid to detect and count live adult T. cal-
lipaeda. Clinical signs indicative of eyeworm infection, such as
lacrimation, conjunctivitis, ocular discharge, keratitis and, ulcers,
were recorded and classiﬁed as absent, mild, moderate or severe.
Each dog was  then weighed and assigned in accordance with a
random treatment allocation plan to one of the treatment groups
(G1: imidacloprid 10% and moxidectin 2.5% spot on, G2: Untreated
control and G3: milbemycin oxime/praziquantel tablets). Both
products were administered according to label instructions. In par-
ticular, Advocate® spot-on to provide a minimum dose of 2.5 mg
moxidectin and 10 mg  imidacloprid/kg and Milbemax® to provide
a minimum dose of 0.5 mg/kg milbemycin oxime and 5 mg/kg praz-
iquantel.
On D7, D14, D28, D35 dogs were physically examined and the
infection level was  assessed by examination of both eyes, includ-
ing conjunctival pouch and third eyelid for live adult T. callipaeda
count and clinical scores. On D7, animals in G3 received a second
treatment with milbemycin oxime/praziquantel tablets according
to product label. On D28, animals in G1 received a second treat-
ment with imidacloprid 10% and moxidectin 2.5% spot-on. At study
closure on D35, the presence of T. callipaeda larvae was assessed
by microscopic examination of samples collected by conjunctival
pouch ﬂushing with 5 mL  of saline solution (0.9%) and preserved
in sterile tubes. Subsequently, T. callipaeda adults were removed.
The tube was centrifuged for 5 min  at 700g. The supernatant was
aspirated and the sediment (1 mL  solution) was  analysed under an
optical microscope (40×) for larval count. Nematode larvae and
adults were morphological identiﬁed according to Skrjabin et al.
(1971) and Otranto et al. (2003b).
From D0 to D35 all the dogs were observed daily by the own-
ers to assess and record abnormalities of the general health and, in
case of abnormal health conditions, the veterinarian was  respon-
sible to examine the dog and to record the results of the clinical
examination.
2.1. Statistical analysis
Sample size was based on superiority of imidacloprid 10% and
moxidectin 2.5% spot-on compared to the untreated control with
respect to the percentage reduction of dogs harbouring adult T. cal-
lipaeda worms. A minimum sample size of 10 dogs per group was
calculated based on an expected prevalence of non-infected dogs of
90.47% (Bianciardi and Otranto, 2005) in treated group and of 23.8%
(Motta et al., 2012) in untreated control group, with 95% Conﬁdence
Level and 90% Power. In order to account for potential dropouts, the
minimum number of animals to be included in the study was  15 in
each group.
Dogs were allocated to study group following a random treat-
ment allocation plan on the basis of an inclusion sequence, in blocks
of three patients each. Each dog per block was randomly assigned
to one of the three treatment groups. The primary variable for the
efﬁcacy evaluation was  the number of dogs showing a complete
elimination of adult eyeworms on D7, D14, D28, D35, by com-
parison of groups G1 and G2. Moreover, as secondary descriptive
parameters, the efﬁcacy of the treatment in the group G3 with
respect to parasitological cure (therapeutic efﬁcacy) and worm
count/severity and/or presence of ocular clinical signs was calcu-
lated and compared with the untreated control group on D7, D14,infection was  calculated for each time point using the following
formula: Efﬁcacy = [(% of animals positive in Untreated group −
% of animals positive in Treated group)/% of animals positive in
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Table 1
Data of the dogs enrolled in the study.
Total G1 G2 G3
Number of animals 47 16 15 16
Age  [months] 38.6 (7–156) 36.7 (7–96) 37.5 (8–156) 41.6 (18–96)
Gender [%] Female/Male 57.4/42.6 56.3/43.8 60.0/40.0 56.3/43.8
Weight [kg] 14.9 (4.8–35.6) 14.7 (6.6–31) 14.0 (5.4–35.6) 15.8 (4.8–34.1)
Hair  length [%]Long/Medium/Short 8.5/51.1/40.4 12.5/43.8/43.8 6.7/60.0/33.3 6.3/50.0/43.8
Table 2
Number and percentage of dogs positive for adult Thelazia callipaeda during the study.
Study day 0 7 14 28 35
G1 16 (100) 0 0 0 0
Efﬁcacy [%] 100* 100* 100* 100*
G2 15 (100) 11 (73.33) 13 (87.67) 11 (73.33) 11 (73.33)
–
G3  16 (100) 5 (31.25) 1 (6.25) 0 0
*
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) p < 0.01 − (**) p < 0.05.
ntreated group] × 100. Effectiveness was claimed if signiﬁcant dif-
erence between groups G1 or G3 with the untreated control group
G2) was demonstrated by Fisher’s Exact Test calculated on contin-
ency tables for parasitological cure with 5% level of signiﬁcance.
n addition, the groups G1 and G3 were compared to each other by
isher’s Exact Test.
Worm count and ocular clinical signs reductions in the treated
roups were compared at each time point (t) with the untreated
ontrol group as follows: % reduction [t] = (Ct0–Ct)/Ct0) × 100,
here Ct0 was the baseline count before treatment and Ct was
he count at time t after treatment for each secondary variable
nder investigation. The signiﬁcance of the worm count reduction
n treated dogs was analysed by ANOVA, with standard statistical
ssumption.
Statistical analysis was planned and conducted in compliance
ith current guidelines (EMA, 2010). Statistical calculations and
andomization were performed with: SPSS® statistical package for
indows, version 13.0, and nQuery + nTerim 3.0 (StatSols), Statis-
ical Solutions® Ltd. 2014, Microsoft.
. Results
The percentage of dogs with different levels of T. callipaeda infec-
ion and symptoms in each eye was homogenous among groups
p < 0.05). Number and percentages of dogs positive for T. calli-
aeda at each study day are reported in Table 2. Efﬁcacy in group
1 (imidacloprid 10% and moxidectin 2.5% spot-on) was  100% at
ach day post treatment (p < 0.01). For the G3 group (milbemycin
xime/praziquantel tablets) efﬁcacy was 57.39% on D7 (p < 0.05),
2.79% on D14 and 100% on D28 and D35 (p < 0.01). G1 and G3
roups have signiﬁcant different efﬁcacy at D7 (p < 0.05) but not at
he following time points. The total number and mean of live adult
. callipaeda worms counted in both eyes is presented in Table 3. The
eduction of the number of worm counted in both eyes was  100%
or the G1 group (imidacloprid 10% and moxidectin 2.5% spot-on)
rom D7 onwards and 90.91% on D7, 97.73% on D14 and 100% on
28 and D35 for the G3 group (milbemycin oxime/praziquantel
ablets). A natural mild reduction in the control group G2 was also
bserved (29.31%, 24.14%, 34.48% and 18.97% on D7, 14, D28 and
35 respectively). The reduction of the mean worm count for T.
allipaeda from both eyes was signiﬁcantly different (p < 0.01) for
he G1 and the G3 group when compared to the control group at
ll post-treatment time points.
Ocular signs associated with T. callipaeda infection included
acrimation, conjunctivitis and discharge. None of the dogs showed92.79* 100* 100*
keratitis or ulcers except one dog in the G3 that showed both symp-
toms on D7. Due to the low occurrence of the different ocular
signs, only lacrimation and conjunctivitis have been statistically
analysed. No overall evidence of adverse effects of the treatments
in the G1 (imidacloprid 10% and moxidectin 2.5% spot-on) and the
G3 (milbemycin oxime/praziquantel tablets) groups were demon-
strated when compared to the control group and a signiﬁcant
difference was  only observed between G2 and G3 for conjunctivitis
affecting left eye on D28.
4. Discussion
The application of the spot on formulation moxidectin 2.5% and
imidacloprid 10% (Advocate®) was  highly effective in the treat-
ment of canine thelaziosis. This formulation showed to be more
effective in the treatment of thelaziosis compared to the admin-
istration of milbemycin oxime/praziquantel tablets (Milbemax®).
Indeed, no worms  were detected following the ﬁrst treatment,
while dogs in the milbemycin oxime/praziquantel tablets group
still had worms  counted on D7 and D14 (i.e. for one week after
the second treatment). These data are in accordance with previous
investigations where a single or two treatments with milbemycin
oxime/praziquantel tablets were effective within seven (72.7%) and
14 (90.9%) days after the administration of the product (Motta
et al., 2012). A single application of imidacloprid 10% and mox-
idectin 2.5% spot-on was effective within ﬁve (90.47%) to nine
(95.23%) days after administration (Bianciardi and Otranto, 2005)
for the treatment of infected dogs. In this study, the spot on for-
mulation moxidectin 2.5% and imidacloprid 10% resulted in the
elimination of 100% of the eyeworms in infected animals within
seven days from a single application, whereas two  administrations
of milbemycin oxime/praziquantel tablets were required to com-
pletely cure T. callipaeda infection 21 days following the second
administration. Moxidectin is absorbed through the skin, reach-
ing maximum plasma concentrations approximately 4–9 days after
treatment in dogs. Following absorption from the skin, mox-
idectin is distributed systemically and is slowly eliminated from
the plasma as manifested by detectable moxidectin concentrations
in plasma throughout the treatment interval of one month (EMA
Advocate, 2016).
The monthly application of milbemycin oxime (Ferroglio et al.,
2008) as well as imidacloprid 10% and moxidectin 2.5% spot-on
(Lechat et al., 2015) showed an efﬁcacy in reducing eyeworm infec-
tion rate of 90% and 100%, respectively. Therefore, the application
of imidacloprid 10% and moxidectin 2.5% spot-on could be success-
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Table  3
Number (and mean) of adult Thelazia callipaeda adult live worms  counted in both eyes.
Study day 0 7 14 28 35
G1 79 (4.94) 0 0 0 0
Reduction [%] 100* 100* 100* 100*
G2 58 (3.87) 41 (2.73) 44 (2.93) 38 (2.53) 47 (3.13)
Reduction [%] 29.31 24.14 34.48 18.97
G3  88 (5.50) 8 (0.50) 2 (0.13) 0 0
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Tasic´-Otasˇevic´, S., Gabrielli, S., Trenkic´-Bozˇinovic´, M.,  Petrovic´, A., Gajic´, B., Colella,
V., Momcˇilovic´, S., Cancrini, G., Otranto, D., 2016. Eyeworm infections in dogs
and in a human patient in Serbia: a one health approach is needed. Comp.
Immunol. Microbiol. Infect. Dis. 45, 20–22.Reduction [%] 90.91*
*) p < 0.01.
ully used for both the treatment and prevention of thelaziosis in
ogs. Considering that in endemic areas the prevalence of the infec-
ion may  be up to 60%, such as in some municipalities of southern
taly (Otranto et al., 2003a), a continuous treatment of animals is
entral for the control of the infection, eventually reducing the risks
or human health. Meanwhile, the prophylaxis against eyeworm
nfection in travelling dogs from a non endemic to an endemic area
nd vice versa is mandatory to limit the introduction of T. callipaeda
n non endemic regions where the competent vector, P. variegata,
s present (Otranto et al., 2006). The safety of the easy-to-apply
f imidacloprid 10% and moxidectin 2.5% spot-on solution in the
reatment of canine thelaziosis is inferred by the lack of any adverse
ffects and clinical signs compared to the control group.
. Conclusion
Advocate® spot on can be recommended for the control of T.
allipaeda infection, considering that this formulation is currently
icensed in Europe for the treatment of a wide range of parasitic
onditions of the dog (e.g., Ctenocephalides felis, Sarcoptes scabiei var.
anis, Demodex canis, Angiostrongylus vasorum, Toxocara canis and,
ncinaria stenocephala) and in the prevention of Diroﬁlaria immi-
is and Diroﬁlaria repens.  Finally, since cases of animal and human
helaziosis are increasingly reported in Europe, the prevention and
reatment of infected dogs is crucial for the control of this zoonotic
nfection.
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